Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU4 | INFLUENZA (SEASONAL) (FLUARIX QUADRIVALENT) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 72RF2 | IM / RA |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 95BJ9 | IM / LA |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | T5727 | IM / RA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y013579 | SC / RA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y013579 | OT / RA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | OT |
No adverse event; HCP reports multiple patients may have received improperly stored PROQUAD since it "was stored in the refrigerator for months" instead of freezer.; This spontaneous report was received from a nurse and refers to a 12-year-old male patient. The patient's medical history, concurrent conditions, drug reactions or allergies were not reported. Concomitant medications included Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Hepatitis b vaccine rHBsAg (yeast) (ENGERIX B), Influenza vaccine inact split 4v (FLUARIX QUADRIVALENT), Polio vaccine inact 3v (Vero) (IPOL), Diphtheria vaccine toxoid;Pertussis vaccine acellular 3-component;Tetanus vaccine toxoid (BOOSTRIX), Meningococcal vaccine A/C/Y/W conj (CRM197) (MENVEO), Hepatitis a vaccine inact (HAVRIX) . On 06-JAN-2025, the patient was vaccinated with the first dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection (valid lot number Y013579, expiration date: 03-FEB-2026), administered by subcutaneous route in right arm, with sterile diluent (BAXTER STERILE DILUENT) for prophylaxis (dose and vaccination scheme were not provided), after a temperature excursion since it "was stored in the refrigerator for months" instead of freezer, with a total time in the range 15 degrees Fahrenheit (F) to 46 degrees F of 1296 (units not provided) since 13-NOV-2024 (reported as 2025, conflicting information) (product storage error). No additional adverse event (AE).
Engerix B; Fluarix quadrivalent; IPOL; Boostrix; Menveo; Havrix; Gardasil 9